摘要
目的:分析沙库巴曲缬沙坦钠在冠心病患者行经皮冠状动脉介入(PCI)治疗中的应用价值。方法:选取2022年5月—2023年3月于石狮市医院心内科经PCI治疗的冠心病患者66例为研究对象,以随机数字表法分为参照组和研究组,各33例。参照组给予贝那普利治疗,研究组给予沙库巴曲缬沙坦钠治疗。比较两组临床疗效、心功能及不良反应。结果:研究组总有效率高于参照组,差异有统计学意义(P=0.021);用药后,两组左室收缩末期内径、左室舒张末期内径、左室收缩末期容积及左室舒张末期容积水平低于用药前,左室短轴缩短率、左室射血分数高于用药前,且研究组优于参照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:沙库巴曲缬沙坦钠在冠心病患者行PCI治疗中的应用价值较高,可提高疗效,改善患者心功能,安全性较高。
Objective:To analyze the application value of sacubitril valsartan sodium in patients with coronary heart disease after percutaneous coronary intervention(PCI).Methods:Sixty-six patients with coronary heart disease treated by PCI in the Department of Cardiology of Shishi Hospital from May 2022 to March 2023 were selected as the study objects,and were divided into the reference group and the study group by random number table method,with thirty-three cases in each group.The control group was given Benazepril and the study group was given sacubitril valsartan sodium.The clinical efficacy,cardiac function and adverse reactions were compared between the two groups.Results:The total effective rate of the study group was higher than that of the reference group,the difference was statistically significant(P=0.021);after medication,left ventricular end-systolic diameter,left ventricular end-diastolic diameter,left ventricular end-systolic volume and left ventricular end-diastolic volume levels in two groups were lower than before medication,left ventricular short-axis shortening rate and left ventricular ejection fraction were higher than before medication,the study group was better than the reference group,and the difference was statistically significant(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Sacubitril valsartan sodium has high application value in PCI treatment of patients with coronary heart disease,which can improve the curative effect,improve the heart function of patients,and have high safety.
作者
蔡茂焕
Cai Maohuan(Department of Cardiovascular Medicine,Shishi Hospital,Shishi 362700,Fujian Province,China)
出处
《中外医药研究》
2024年第14期48-50,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
关键词
冠心病
沙库巴曲缬沙坦钠
经皮冠状动脉介入
心功能
Coronary heart disease
Sacubitril valsartan sodium
Percutaneous coronary intervention
Cardiac function
